Fexofenadine in Patients With Active Rheumatoid Arthritis

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling

Key facts

Study ID

NCT05264025

Run by

October 6 University

People needed

80

Starts

2022-06-01

Expected to finish

2026-01-01

Last updated by the study team

2025-07-31

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Moderate to severe RA (disease activity score-28 joints: DAS-28 > 3.2) were recruited.
• Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
• Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.

You may not qualify if…

• History of biological DMARDS.
• History/presence of acute heart disease, liver and kidney diseases, COPD
• Intolerance or allergy to fexofenadine or methotrexate
• Alcohol abuse
• Any changes in using medication (changing the dosage or type of medicines
• Receive hormone replacement therapy, warfarin, and other anticoagulants

Where it is running

• Beni-Suef Hospital — Banī Suwayf, Egypt (enrolling)
• Faculty of Medicine - Beni Suef Hospital — Banī Suwayf, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.